Global B-cell lymphoma treatment Market – Industry Trends and Forecast to 2030

B-cell Lymphoma Treatment Market Analysis and Size   

Lymphoma is a type of cancer that starts from lymphocytes. Hodgkin’s and non-Hodgkin’s lymphoma are the two main kinds of lymphoma. B-cell lymphoma are non-Hodgkin’s lymphoma. Among the people with non-Hodgkin lymphoma, about 85 percent have B-cell lymphoma.

According to the American Cancer Society, about 3 out of 4 people will have no signs of disease after the initial treatment, and many are cured. Hairy cell leukemia (HCL) is rare & about 700 people in the United States are diagnosed with it yearly.

Data Bridge Market Research analyses that the B-cell lymphoma treatment Market, which was USD 6,360.75 in 2022, would rocket up to USD 13,145.36 million by 2030 and is expected to undergo a CAGR of 8.4% during the forecast period. “Diffuse Large B-Cell Lymphoma (DLBCL)” dominates the type segment of the B-cell lymphoma treatment market owing to the growing large number of cases and rising prevalence. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

B-cell Lymphoma Treatment Market Scope and Segmentation

Market Definition

B-cell lymphoma treatment encompasses a range of therapeutic approaches to combating cancerous B-cells in the lymphatic system. Chemotherapy remains a cornerstone in managing B-cell lymphomas, often combined with targeted therapies. Immunotherapies, such as immune checkpoint inhibitors and CAR-T cell therapies, have revolutionized treatment outcomes for specific B-cell lymphoma subtypes. Research efforts focus on personalized medicine approaches to tailor treatment based on individual patient characteristics and the identification of novel therapeutic targets. The ultimate goal of B-cell lymphoma treatment is to achieve remission, improve patient outcomes, and enhance the quality of life for individuals affected by this disease.

B-cell Lymphoma Treatment Market Dynamics

Drivers

• Increasing Incidence of B-cell lymphomas

The incidence of B-cell lymphomas, including subtypes such as diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and chronic lymphocytic leukemia (CLL), is rising globally. The growing patient population drives the demand for effective treatment options and fuels the expansion of the market.

• Advancements in Treatment options

The continuous advancements in treatment options have significantly improved outcomes for B-cell lymphoma patients. Targeted therapies, immunotherapies, and CAR-T cell therapies have emerged as powerful tools in the fight against B-cell lymphomas, driving market growth and offering new treatment options.

Opportunities

• Advancements in Targeted Therapies:

Targeted therapies, such as monoclonal antibodies and small molecule inhibitors, have shown promising results in treating B-cell lymphomas. There is an opportunity to refine and expand targeted therapies to improve treatment outcomes, minimize side effects, and overcome resistance mechanisms.

• Rising Personalized Medicine

The advancement of precision medicine approaches and the identification of predictive biomarkers can help tailor treatment strategies for individual patients. This includes using genomic profiling and molecular diagnostics to identify specific genetic alterations and biomarkers that can guide treatment decisions and enhance therapeutic outcomes.

Restraints/Challenges

Various obstacles may restrain the expansion of the B-cell lymphoma treatment market. These challenges include costly treatments, adverse effects associated with long-term therapies, development of drug resistance.  These factors can impede market growth and pose barriers for market players in the forecast period of 2023-2030.

This B-cell lymphoma treatment Market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the B-cell lymphoma treatment Market, contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In March 2023, Bristol Myers Squibb (NYSE: BMY) has announced that the European Commission (EC) approved Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma (HGBCL), primary mediastinal large B-cell lymphoma (PMBCL) and follicular lymphoma grade 3B (FL3B), who relapsed within 12 months from completion of or are refractory to, first-line chemoimmunotherapy. This approval covers all European Union (EU) member states. This has helped the company to expand its product portfolio

• In March 2023, AstraZeneca announced that Calquence (acalabrutinib), a next-generation, selective Bruton’s tyrosine kinase (BTK) inhibitor, has been conditionally approved in China for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. This has helped the company to expand its product portfolio.

Global B-cell Lymphoma Treatment Market Scope

The B-cell lymphoma treatment market is segmented on the basis of type, stages, treatment, end users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Diffuse Large B-Cell Lymphoma (DLBCL)
• Lymphoplasmacytic Lymphoma
• Hairy Cell Leukemia
• Primary Central Nervous System (CNS) Lymphoma
• Primary Intraocular Lymphoma
• Others

Stages

• Stage I
• Stage II
• Stage III
• Stage IV
• Others

Treatment

• Radiation
• Chemotherapy
• Immune Therapy
• Stem Cell Transplant
• Others

End Users

• Hospitals
• Specialty Clinics
• Home Healthcare
• Others

Distribution Channel

• Direct Tender
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

B-cell Lymphoma Treatment Market Regional Analysis/Insights

The B-cell lymphoma treatment Market is analyzed and market size insights and trends are provided by country, type, stages, treatment end user and distribution channel as referenced above.

The countries covered in this market report are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Saudi Arabia, U.A.E, South Africa, Egypt, Israel, rest of Middle East and Africa, Brazil, Argentina and rest of South America.

North America is dominating the market due to the presence of an-advanced healthcare system supporting strong research and development activities for B-cell lymphoma treatment and also due to the increased consumption of oncology drugs for cancer treatment.

Asia-Pacific is expected to grow the market in the forecast period of 2023-2030 because of rising healthcare infrastructure and government and pharmaceutical initiatives for better treatment.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure growth Installed base and New Technology Penetration

The B-cell lymphoma treatment Market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for B-cell lymphoma treatment Market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the B-cell lymphoma treatment Market. The data is available for historic period 2010-2020.

Competitive Landscape and B-cell lymphoma treatment Market Share Analysis

The B-cell lymphoma treatment Market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to B-cell lymphoma treatment Market.

Some of the major players operating in the B-cell lymphoma treatment market are:

• Pfizer Inc. (U.S.)
• Celgene Corporation (U.S.)
• Eli Lilly & Company (U.S.)
• Novartis AG (Switzerland)
• Genentech Inc. (U.S.)
• AstraZeneca (U.K.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Eisai Co., Ltd (Japan)
• Amgen Inc. (U.S.)
• Merck & Co., Inc. (U.S.)
• Bristol-Myers Squibb Company (U.S)
• Johnson & Johnson Services (U.S.)
• Abbott. (U.S.)
• Takeda Pharmaceutical Company Ltd. (Japan)
• Seattle Genetics, Inc. (U.S.)

SKU-59631